SCHEMBL7814993

SCHEMBL7814993

Cn1[c]nc2cc(F)cc(F)c21

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7814909 0.77 — —
SCHEMBL5982858 0.69 PDE10A (0.31) —
SCHEMBL1831006 0.69 KMT2A (0.38) —
SCHEMBL7814921 0.68 CYP11B1 (0.36) —
SCHEMBL2157981 0.67 CYP11B1 (0.39) —
SCHEMBL21187466 0.67 DPP4 (0.47) —
SCHEMBL20698307 0.67 KEAP1 (0.35) —
SCHEMBL4272934 0.66 TRPV4 (0.38) —
SCHEMBL7805132 0.64 NQO2 (0.36) —
SCHEMBL7810993 0.63 PRPS1 (0.36) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0745600-B1 Benzimidazole derivatives, their preparation and their therapeutic use SANKYO CO (JP) 2001-10-24 — — EP disclosed
US-5886014-A TREATMENT AND/OR PROPHYLAXIS OF A VARIETY OF DISORDERS, INCLUDING HYPERLIPEMIA, HYPERGLYCEMIA, OBESITY, IMPAIRED GLUCOSE TOLERANCE (IGT), INSULIN RESISTANCE AND DIABETIC COMPLICATIONS SANKYO COMPANY, LIMITED (JP) 1999-03-23 — — US disclosed
EP-0745600-A1 Benzimidazole derivatives, their preparation and their therapeutic use SANKYO COMPANY LIMITED (JP) 1996-12-04 — — EP disclosed
Send feedback